Rigel Pharmaceuticals, Inc
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer. Its business centers on developing, commercializing, and licensing small-molecule medicines, including TAVALISSE for chronic immune thrombocytopenia and REZLIDHIA for relapsed or refractory AML, with commercial activity in the United States and partnered markets outside the U.S.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved medicines sold directly or through partners for blood disorders and leukemia.
Partnered commercialization, royalties, milestones, and drug supply tied to out-licensed assets.
Contract revenue tied to government-supported development or research programs.
Products
Reported · share of revenue- Gross Product83.3 %
- Release of Share Cost Liability10.7 %
- Royalty Delivery of Drug Supplies and Others5.1 %
- Development Milestones0.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Rigel sells primarily to hematologists and hematologist-oncologists in the U.S. who treat chronic adult ITP and AML patients. Its products also reach patients through specialty pharmacies, wholesalers, group purchasing organizations, and partner companies in ex-U.S. markets. For partnered products, the customer is often a pharmaceutical licensee that buys drug supply, pays royalties, or funds milestone-based collaboration arrangements.
Prescribe TAVALISSE and REZLIDHIA for patients with chronic ITP or AML.
Distribute commercial product to patients and support access and fulfillment.
Buy drug supply, pay royalties, and fund milestones under global agreements.
Provide contract funding for selected development or preparedness programs.
Strategy
Rigel’s strategy is to commercialize its approved hematology products while extending their reach through licensing and regional partners. It also seeks to expand the value of its pipeline and partnered assets through development programs, regulatory approvals, and collaboration-based monetization. Patient access support and reimbursement services are part of the commercial model because they help convert prescriptions into realized sales.
The product is a core revenue driver and depends on specialist prescribing and access.
A second approved product diversifies disease exposure and revenue sources.
Licensing and supply agreements extend reach without requiring full direct infrastructure.
Geography
Rigel is headquartered in the United States and generates its direct commercial sales primarily in the U.S. through a physician-focused hematology sales force. It also has commercial and licensing activity outside the U.S. through partners in Europe, the UK, Japan, Korea, Canada, Israel, and other territories. Geography matters because the company’s revenue mix depends on U.S. product sales versus partner-driven international royalties, milestones, and supply revenue.
Risks
Rigel depends on a small number of products and disease areas, so demand shortfalls, competitive therapies, or generic entry could materially affect revenue. The business also relies on third-party manufacturers, distributors, and collaboration partners, which creates supply-chain and execution risk across both commercial and development activities. Because reimbursement and patient access are central to prescription conversion, changes in payer policy, rebates, or support-program economics can also pressure realized sales.
- Product concentrationImpact: HighLikelihood: Medium
A limited commercial portfolio means setbacks in one product can disproportionately affect revenue.
Exposure: TAVALISSE and REZLIDHIA
- Generic and competitive pressureImpact: HighLikelihood: Medium
Specialty pharmaceuticals face branded and generic competition that can compress demand and pricing.
Exposure: TAVALISSE in chronic ITP
- Reimbursement and access pressureImpact: HighLikelihood: Medium
Net sales depend on payer coverage, rebates, chargebacks, and patient assistance economics.
Exposure: U.S. specialty pharmacy channel
- Supply chain and third-party dependenceImpact: MediumLikelihood: Medium
The company relies on outside manufacturers, distributors, and logistics providers to deliver product.
Exposure: Commercial product supply and clinical materials
- Partner and licensing executionImpact: MediumLikelihood: Medium
International revenue depends on counterparties meeting commercialization, supply, and milestone obligations.
Exposure
Accounting
Judgemental itemsNet sales are reduced by estimated rebates, chargebacks, returns, and discounts.
Impact: Affects reported revenue and gross-to-net realization
Upfront fees, milestones, royalties, and supply revenue are recognized under different timing rules.
Impact: Can create lumpy quarterly revenue
Some collaboration payments are deferred until remaining obligations are satisfied.
Impact: Impacts timing of reported revenue
Cumulative losses and NOL usage assumptions affect whether tax assets are realizable.
Impact: Can materially affect tax expense and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Last updated: 24/09/2026